


**PE/Fire™ 700 anti-human CD19**

<b>Catalog # /</b>	2111375 / 25 tests
<b>Size:</b>	2111380 / 100 tests
<b>Clone:</b>	HIB19
<b>Isotype:</b>	Mouse IgG1, κ
<b>Reactivity:</b>	Human, Other
<b>Preparation:</b>	The antibody was purified by affinity chromatography and conjugated with PE/Fire™ 700 under optimal conditions.
<b>Formulation:</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)
<b>Workshop Number:</b>	V CD19.11
<b>Concentration:</b>	Lot-specific



Human peripheral blood lymphocytes were stained with anti-human CD20 FITC and anti-human CD19 PE/Fire™ 700 (clone HIB19) (left), or stained with anti-human CD20 FITC only (right).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

\* PE/Fire™ 700 has a maximum excitation of 565 nm and a maximum emission of 695 nm.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections<sup>8</sup> and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

**Application References:**

- Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
- Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Bradbury L, et al. 1993. *J. Immunol.* 151:2915.
- Joseph A, et al. 2010. *J. Virol.* 84:6645. [PubMed](#)
- Wang X, et al. 2010. *Haematologica.* 95:884. (FC) [PubMed](#)
- Walker JD, et al. 2009. *J. Immunol.* 182:1548. (Block) [PubMed](#)
- Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
- Hansen A, et al. 2002. *Arthritis Rheum.* 46:2160. (IHC)
- Stoeckius M, et al. 2017. *Nat. Methods.* 14:865. (PG)
- Peterson VM, et al. 2017. *Nat. Biotechnol.* 35:936. (PG)

**Description:** CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

**Antigen** 1. Tedder T, *et al.* 1994. *Immunol. Today* 15:437.  
**References:** 2. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.